Imugene CEO on Phase 1b azer-cel data: second complete response

Imugene Ltd MD and CEO Leslie Chong talked with Proactive about the company reporting a second complete response in the concurrent Bruton Tyrosine Kinase inhibitor, or BTKi, cohort of its ongoing Phase 1b azer-cel trial. The latest response was recorded in the first mantle cell lymphoma, or MCL, patient treated in the azer-cel Phase 1b study. The patient had previously received and failed BTKi therapy before achieving a complete response at the Day 28 assessment. The result follows closely after Imugene Ltd reported its first complete response in the concurrent BTKi cohort, highlighting a second early response in a patient group that has relapsed on or is refractory to BTKi therapy. Chong said MCL can be an aggressive disease and that patients who progress after BTKi therapy can face a steep decline. azer-cel is being studied in combination with an existing approved therapy, to help make BTKi treatment work again. She also discussed increased business development activity and on...